Docoh
Loading...

TSHA Taysha Gene Therapies

Press releases

From Benzinga Pro
Taysha Gene Therapies to Participate in Upcoming November Investor Healthcare Conferences
8 Nov 21
Press Releases
Stifel 2021 Virtual Healthcare Conference on November 15, 2021 at 11:20 am ET Jefferies London Healthcare Conference November 17, 2021 at 12:20 pm GMT 4th Annual Evercore ISI HealthCONx Virtual Conference on November
Taysha Gene Therapies Announces Publication of Positive Proof-of-Concept Preclinical Data for an AAV-mediated UBE3A Gene Replacement Approach Demonstrating Therapeutic Potential for The Treatment of Angelman Syndrome in the Journal JCI Insight
25 Oct 21
Press Releases
AAV-mediated UBE3A gene replacement recapitulates endogenous isoform ratios by replacing both the short and long isoforms of UBE3A in key regions of the brain, leading to improvements in motor learning, behavior
Taysha Gene Therapies to Participate in Upcoming Gene Therapy Summit
21 Oct 21
Press Releases
Jefferies Gene Therapy & Editing Summit on October 28 at 11:00 am ET Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing
Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-106 for the Treatment of Angelman Syndrome
12 Oct 21
Press Releases
Virtual event on Tuesday, October 26, 2021, at 10:00 a.m. ET will provide an overview of Angelman syndrome, natural history data, gene therapy treatment mechanisms and Taysha's clinical development strategy Taysha Gene
Taysha Announces Exclusive Option from UTSW to License Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program for CLN7 Disease, a Research Collaboration with UTSW to Develop Next-Generation Construct for CLN7 and a Grant Award to Batten Hope
5 Oct 21
Press Releases
CLN7 program currently in Phase 1 clinical proof-of-concept trial with preliminary data anticipated by year-end 2021 Intrathecal dosing of the high dose first-generation construct resulted in nearly complete
Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis
29 Sep 21
Press Releases
TSHA-101 is the first and only bicistronic vector being developed in a Phase 1/2 clinical study to date Preliminary clinical safety and biomarker data from the Queen's University study expected by year-end No approved
Taysha Gene Therapies to Participate in Upcoming October Investor Healthcare Conferences
28 Sep 21
Press Releases
Chardan's 5th Annual Genetic Medicines Conference on October 5 at 1:30 pm ET President, Founder and Chief Executive Officer to participate in the "What's Next for Advanced Therapies" panel at Meeting on the Mesa on
Taysha Receives Orphan Drug Designation from the European Commission for TSHA-102 for the Treatment of Rett Syndrome
22 Sep 21
Press Releases
Preclinical data provide quantitative evidence of TSHA-102's ability to exhibit genotype-dependent regulation of MECP2 gene expression across different brain regions on a cell-by-cell basis Significant survival benefit
Taysha Gene Therapies Announces Publication of Positive Preclinical Data for TSHA-104 Demonstrating Therapeutic Potential in SURF1-associated Leigh Syndrome in Journal Molecular Therapy: Methods & Clinical Development
15 Sep 21
Press Releases
TSHA-104 restored to normal levels elevation of blood lactate on exhaustive exercise in dose-dependent manner in SURF1 knockout mice TSHA-104 increased COX1 activity in brain and muscle in dose-dependent manner in
Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-102 for the Treatment of Rett Syndrome
8 Sep 21
Press Releases
Virtual event on Wednesday, September 22, 2021, at 10:00 a.m. ET will provide an overview of Rett syndrome, discuss natural history, and the TSHA-102 program and clinical development strategy Taysha Gene Therapies,